NASDAQ:TRVNTrevena Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Trevena Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.30 -0.02 (-1.52 %) (As of 05/29/2020 04:00 PM ET) Add Compare Share Today's Range$1.20Now: $1.30▼$1.3250-Day Range$0.51MA: $0.88▼$1.4052-Week Range$0.46Now: $1.30▼$1.52Volume2.20 million shsAverage Volume1.38 million shsMarket Capitalization$139.34 millionP/E RatioN/ADividend YieldN/ABeta2.51 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of treatment options that target and treat diseases affecting the central nervous system. Its product candidates include Oliceridine injection, a G protein biased mu-opioid receptor (MOR) ligand that has completed Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is warranted; TRV250, a G protein biased delta- opioid receptor ligand, which is in Phase I clinical study for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain; TRV027 for the treatment of acute heart failure; and TRV045, a novel S1P modulator for managing chronic pain. The company was founded in 2007 and is headquartered in Chesterbrook, Pennsylvania.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingTrevena has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.50, Trevena has a potential upside of 169.2% from its current price of $1.30.Amount of Analyst CoverageTrevena has only been the subject of 1 research reports in the past 90 days. Previous Next 3.3 Community Rank Outperform VotesTrevena has received 585 “outperform” votes. (Add your “outperform” vote.)Underperform VotesTrevena has received 292 “underperform” votes. (Add your “underperform” vote.)Community SentimentTrevena has received 66.70% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Trevena and other stocks. Vote “Outperform” if you believe TRVN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe TRVN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldTrevena does not currently pay a dividend.Dividend GrowthTrevena does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Trevena insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.20% of the stock of Trevena is held by insiders.Percentage Held by InstitutionsOnly 16.13% of the stock of Trevena is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Trevena are expected to decrease in the coming year, from ($0.25) to ($0.26) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Trevena is -4.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Trevena is -4.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTrevena has a P/B Ratio of 4.81. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.36 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TRVN Previous Symbol CUSIPN/A CIK1429560 Webwww.trevena.com Phone610-354-8840Debt Debt-to-Equity Ratio0.27 Current Ratio11.37 Quick Ratio11.37Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$30,000.00 Price / Sales4,644.51 Cash FlowN/A Price / Cash FlowN/A Book Value$0.27 per share Price / Book4.81Profitability EPS (Most Recent Fiscal Year)($0.27) Net Income$-24,870,000.00 Net MarginsN/A Return on Equity-74.87% Return on Assets-48.90%Miscellaneous Employees29 Outstanding Shares107,181,000Market Cap$139.34 million Next Earnings Date8/5/2020 (Estimated) OptionableOptionable NASDAQ:TRVN Rates by TradingView Receive TRVN News and Ratings via Email Sign-up to receive the latest news and ratings for TRVN and its competitors with MarketBeat's FREE daily newsletter. Trevena (NASDAQ:TRVN) Frequently Asked Questions How has Trevena's stock been impacted by COVID-19 (Coronavirus)? Trevena's stock was trading at $0.6984 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, TRVN shares have increased by 86.1% and is now trading at $1.30. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Trevena? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Trevena in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Trevena. When is Trevena's next earnings date? Trevena is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Trevena. How were Trevena's earnings last quarter? Trevena Inc (NASDAQ:TRVN) issued its earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, meeting the Zacks' consensus estimate of ($0.06). View Trevena's earnings history. What price target have analysts set for TRVN? 1 Wall Street analysts have issued 1 year price targets for Trevena's stock. Their forecasts range from $3.50 to $3.50. On average, they anticipate Trevena's stock price to reach $3.50 in the next twelve months. This suggests a possible upside of 169.2% from the stock's current price. View analysts' price targets for Trevena. Has Trevena been receiving favorable news coverage? News coverage about TRVN stock has trended neutral this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Trevena earned a daily sentiment score of 0.5 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutTrevena. Are investors shorting Trevena? Trevena saw a increase in short interest in April. As of April 30th, there was short interest totaling 4,090,000 shares, an increase of 26.6% from the April 15th total of 3,230,000 shares. Based on an average trading volume of 1,120,000 shares, the short-interest ratio is presently 3.7 days. Approximately 4.6% of the company's shares are sold short. View Trevena's Current Options Chain. Who are some of Trevena's key competitors? Some companies that are related to Trevena include Athersys (ATHX), Corbus Pharmaceuticals (CRBP), Clovis Oncology (CLVS), Crinetics Pharmaceuticals (CRNX), Urogen Pharma (URGN), Passage Bio (KROS), Basilea Pharmaceutica (BPMUF), Atreca (BCEL), AnaptysBio (ANAB), Trillium Therapeutics (TRIL), Viking Therapeutics (VKTX), AC Immune (ACIU), NewLink Genetics (NLNK), Passage Bio (IMRA) and Emisphere Technologies (EMIS). View all competitors. What other stocks do shareholders of Trevena own? Based on aggregate information from My MarketBeat watchlists, some companies that other Trevena investors own include Conatus Pharmaceuticals (CNAT), Novavax (NVAX), ADMA Biologics (ADMA), Amplify Energy (AMPY), Amplify Energy (AMPY), Sorrento Therapeutics (SRNE), AEterna Zentaris (AEZS), Chesapeake Energy (CHK), SCYNEXIS (SCYX) and Miragen Therapeutics (MGEN). Who are Trevena's key executives? Trevena's management team includes the following people: Ms. Carrie L. Bourdow, Pres, CEO & Director (Age 56)Dr. Howard A. Rockman M.D., Scientific Founder, Consultant and Member of Scientific Advisory BoardMr. John P. Hamill, VP of Fin. (Age 55)Erin Clark, Sr. Director of Corp. Strategy & Investor RelationsMr. Michael Catalano, VP of Marketing What is Trevena's stock symbol? Trevena trades on the NASDAQ under the ticker symbol "TRVN." Who are Trevena's major shareholders? Trevena's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Geode Capital Management LLC (0.61%), WINTON GROUP Ltd (0.56%) and Summit X LLC (0.06%). Company insiders that own Trevena stock include John P Hamill, Leon O Moulder Jr and Maxine Gowen. View institutional ownership trends for Trevena. Which major investors are selling Trevena stock? TRVN stock was sold by a variety of institutional investors in the last quarter, including Geode Capital Management LLC. View insider buying and selling activity for Trevena. Which major investors are buying Trevena stock? TRVN stock was purchased by a variety of institutional investors in the last quarter, including WINTON GROUP Ltd, and Summit X LLC. Company insiders that have bought Trevena stock in the last two years include John P Hamill, Leon O Moulder Jr, and Maxine Gowen. View insider buying and selling activity for Trevena. How do I buy shares of Trevena? Shares of TRVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Trevena's stock price today? One share of TRVN stock can currently be purchased for approximately $1.30. How big of a company is Trevena? Trevena has a market capitalization of $139.34 million and generates $30,000.00 in revenue each year. The biopharmaceutical company earns $-24,870,000.00 in net income (profit) each year or ($0.27) on an earnings per share basis. Trevena employs 29 workers across the globe. What is Trevena's official website? The official website for Trevena is www.trevena.com. How can I contact Trevena? Trevena's mailing address is 955 Chesterbrook Boulevard Suite 110, Chesterbrook PA, 19087. The biopharmaceutical company can be reached via phone at 610-354-8840 or via email at [email protected] This page was last updated on 5/30/2020 by MarketBeat.com Staff
